Compare TPR & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPR | ILMN |
|---|---|---|
| Founded | 1941 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3B | 26.7B |
| IPO Year | 2000 | 2000 |
| Metric | TPR | ILMN |
|---|---|---|
| Price | $125.14 | $216.43 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 17 |
| Target Price | ★ $145.44 | $124.24 |
| AVG Volume (30 Days) | ★ 3.1M | 2.0M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 786.59 | 170.87 |
| EPS | ★ 7.27 | 2.22 |
| Revenue | ★ $5,880,000,000.00 | $4,343,000,000.00 |
| Revenue This Year | $12.39 | $6.47 |
| Revenue Next Year | $5.36 | $5.58 |
| P/E Ratio | ★ $16.95 | $102.56 |
| Revenue Growth | ★ 31.01 | N/A |
| 52 Week Low | $93.00 | $88.00 |
| 52 Week High | $164.80 | $231.81 |
| Indicator | TPR | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 31.41 | 66.87 |
| Support Level | N/A | $117.73 |
| Resistance Level | $133.72 | N/A |
| Average True Range (ATR) | 4.21 | 8.37 |
| MACD | -1.85 | 2.43 |
| Stochastic Oscillator | 2.28 | 79.11 |
Based in New York City, Tapestry is the parent company of accessories and fashion brand Coach, which accounted for 80% of its revenue and well over 90% of its operating profit in fiscal 2025. Handbags accounted for 58% of the brand's fiscal 2025 revenue. Coach products are sold through more than 950 company-owned stores, company-operated digital channels, and wholesale partners in North America, Asia, and Europe. Tapestry also owns Kate Spade (17% of fiscal 2025 revenue), which operates about 335 worldwide stores and generated 52% of its sales from handbags in fiscal 2025. Kate Spade is known for its colorful patterns and graphics. Tapestry sold its smallest brand, luxury footwear maker Stuart Weitzman, to Caleres in August 2025.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.